Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients

AIDS

Volumn 11, Issue 14, 1997, Pages

  Fätkenheuer, Gerd ^a   Theisen, Albert ^b   Rockstroh, Jürgen ^b   Grabow, Tanja ^a   Wicke, Christian ^a   Becker, Katja ^a   Wieland, Ulrike ^a   Pfister, Herbert ^a   Reiser, Marcel ^a   Hegener, Petra ^a   Franzen, Caspar ^a   Schwenk, Achim ^a   Salzberger, Bernd ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

AIDS; Antiretroviral therapy; HIV; HIV RNA; Protease inhibitors; Treatment failure; Viral load

Indexed keywords

CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; TREATMENT FAILURE;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SAQUINAVIR; TREATMENT FAILURE;

EID: 0344015847     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199714000-00001     Document Type: Article

References (23)

1. Hammer SM: Advances in antiretroviral therapy and viral load monitoring. AIDS 1996, 10 (suppl A):S1-S11.
2. O'Brien TR, Blattner WA, Waters D, et al.: Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996, 276:105-110.
3. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996. 335:1091 1098.
4. O'Brien WA, Harligan PM, Daar ES, Simberkoff MS, Hamilton JD, VA Cooperative Study Group on AIDS: Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
5. Hughes MD, Johnson VA, Hirsch MS, et al.: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997, 126:926 938.
6. Cameron DW, Heath-Chiozzi M, Kravick S, et al.: Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir update. XI International Conference of AIDS. Vancouver, July 1996 [abstract MoB411].
7. Lalezari J, Haubrich R, Burger HU: Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV) plus HIVID (zalcitabine, ddC). XI International Conference on AIDS. Vancouver, July 1996 [abstract LBB6033].
8. 3. Eigth Congress of Clinical Microbiology and Infectious Diseases. Lausanne, May 1997 [abstract 90A].
9. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996, 276:146-154.
10. British HIV Association: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
11. Saag MS: Use of HIV viral load in clinical practice: back to the future. Ann Intern Med 1997, 126:983 985.
12. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
13. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
14. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
15. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
16. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997, 277:1962-1969.
17. Vandamme AM, Van Dooren S, Kok W, et al.: Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. J Virol Methods 1995, 52:121-32.
18. Vandamme AM, Schmit JC, Van Dooren S, et al.: Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:127-139.
19. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996, 334:1011-1017.
20. Walmsley S, Walach C, Fletcher D, et al.: Efficacy of saquinavir in patients with advanced HIV infection. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997, [abstract 192].
21. Noble S, Faulds D: Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996. 52:93 112.
22. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
23. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Fodd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.